http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101984956-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6a6f422b091ba12ea61d4adbf1b0e8e |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19 |
| filingDate | 2010-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0e4ab3a2ef2a8372977edc1cfcda5a6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7dbac7f93ae6b634645f94b4b6635e95 |
| publicationDate | 2011-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-101984956-A |
| titleOfInvention | Application of pH sensitive type amphiphilic graft polyphosphazene for preparing administration vesicle |
| abstract | The invention discloses an application of pH sensitive type amphiphilic graft polyphosphazene for preparing a pH response type amphiphilic graft polyphosphazene administration vesicle. The administration vesicle contains pH response type amphiphilic graft polyphosphazene and drugs, wherein metered by the total weight of the drugs and the pH response type amphiphilic graft polyphosphazene, the weight percent of the drugs is 0.001%-30%, and the weight percent of the pH response type amphiphilic graft polyphosphazene is 70%-99.999%. The pH response type amphiphilic graft polyphosphazene is a graft polymer which is characterized in that a polyphosphazene chain segment is taken as a framework, a first graft group and a second graft group are connected on a phosphorus atom, and a third graft group is selectively connected on the phosphorus atom. The administration vesicle can load one or two water-soluble drugs and hydrophobic drugs, has pH responsiveness in drug release, can quickly release drugs near tumor tissues or in tumor cells at the fixed time, and has a function of reversing the multidrug resistance of tumor cells. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108478526-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108478526-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110218313-A |
| priorityDate | 2010-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407803098 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID147144457 |
Total number of triples: 19.